pharma news today glp-1 2025 A biopharmaceutical company is looking for ways to slim down household pets. Okava Pharmaceuticals, a San Francisco based company, is introducing a new clinical weight loss study for cats. MEOW-1, as Scaling for the GLP-1 Revolution

Biotransformation and elimination may also be impaired, leading to poor detoxification and recirculation of toxins that worsen symptoms

This medicine may not be right for you

Some start with growth hormone optimization and see significant improvements in skin, sleep, and energy

M.Cifuentes-PaganoE.PaganoP

For instance, In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions

Lancet Gastroenterol Hepatol 9:957964 Feighery AM, Oblizajek NR, Vogt MNP, Bi D, League J 3rd, Buttar NS, Prichard DO (2023) Retained food during esophagogastroduodenoscopy is a risk factor for gastric-to-pulmonary aspiration